Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from ItalyL. Pasulo, Giuliana Cologni, M. Gambato et al.|Digestive and Liver Disease|2019Cited by 1
Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patientsM. Gambato, M.G. Pigozzi, Angiola Spinetti et al.|Digestive and Liver Disease|2019Cited by 1
THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from ItalyL. Pasulo, Antonio Albanese, Roberto Gulminetti et al.|Journal of Hepatology|2019Cited by 1
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patientsMartina Gambato, Marie Graciella Pigozzi, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 1
Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study GroupElisabetta Degasperi, S. Fagiuoli, L. Pasulo et al.|Digestive and Liver Disease|2018Cited by 0